6-K ·Filed Jul 30, 2026

ICLR

ICON PLC
BEARISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001628280-26-050844
Notable filing: 6-K
Actionable Insight ▼ Bearish

The earnings deterioration is severe and structural — margin compression is accelerating while the company navigates accounting restatement fallout, material control weaknesses, and an expanding securities class action. The $750M buyback authorization provides optionality but was unused in H1, suggesting management is conserving liquidity. Watch for further margin erosion in H2 2026 and any developments in the securities litigation (motion to dismiss due September 1, 2026). The $750M 2027 Notes maturity in May 2027 is the next major refinancing event.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d
ICLR ▲ +2.53% at T+20d
SHORT call ✗ call lost -2.53% · α vs SPY +1.43% · entry $165.53 → $169.72
Next anchor: T+60d in 21d
Latest observation: T+42 +23.29% FF3 residual α
Entry anchored
Jul 29, 03:59 PM ET
via exchange tick
T+1d
-1.19%
call +1.19% · α +1.89%
$163.57
settled 2mo ago
T+5d
-2.63%
call +2.63% · α +6.26%
$161.17
settled 8w ago
T+20d
+2.53%
call -2.53% · α +1.43%
$169.72
settled 5w ago
T+60d
—
call — · α —
—
in 21d

Price Chart

Loading chart...

Executive Summary

ICON plc reported Q2 2026 results with revenue essentially flat (+1.2% to $2.06B) but net income collapsed 64% to $72.6M from $203.5M a year ago, driven by direct cost margin expansion (76.8% vs 71.4% of revenue), a $32.9M loss on the Symphony disposal, and $20.9M in restructuring charges. Operating income fell 40% to $137.8M. The filing follows the May 2026 20-F that restated FY2023/2024 financials due to improper revenue recognition and disclosed material internal control weaknesses, with an ongoing securities class action now expanded to include additional defendants and claims.

Key Facts

  • Q2 2026 revenue $2.06B vs $2.04B (+1.2%); net income $72.6M vs $203.5M (-64.3%)
  • Diluted EPS $0.94 vs $2.56 (-63.3%); H1 2026 diluted EPS $2.29 vs $4.54 (-49.6%)
  • Operating margin fell to 6.7% from 11.3% as direct costs rose to 76.8% of revenue from 71.4%
  • Recorded $32.9M pre-tax loss on disposal of Symphony Health Solutions (May 8, 2026)
  • Restructuring charges of $20.9M in Q2 ($31.0M YTD) for workforce reduction
  • Securities class action expanded: Second Amended Complaint filed June 26, 2026 adds new plaintiffs, current CFO, and a scheme liability claim under Section 10(b)
  • Backlog (unsatisfied performance obligations) grew to $15.7B from $14.9B at year-end 2025
  • Cash from operations improved to $448.3M from $414.4M; cash balance $928.4M
  • Drew down $500M Bridge Secured Credit Facility on July 15, 2026 to repay maturing 2.875% Senior Secured Notes
  • No share repurchases in H1 2026; $750M authorization remains unused

Financial Impact

Net income declined $130.9M YoY in Q2 2026; operating income fell $93.1M; direct cost ratio expanded 540bps to 76.8% of revenue

revenuenet incomeepsoperating margindirect costs

Risk Factors

  • Securities class action could result in material settlement or judgment; Second Amended Complaint expands scope
  • Direct cost margin expansion (76.8% vs 71.4%) signals pricing pressure and/or cost overruns that may persist
  • Material weaknesses in internal controls over financial reporting remain unresolved, increasing restatement risk
  • $750M 2027 Notes mature May 2027 — refinancing risk if credit profile continues to weaken
  • Ongoing restructuring suggests demand or operational challenges requiring headcount reduction

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
67% bullish (24 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001628280-26-050844
Document: icon-ex171guarantorschedul.htm0001628280-26-050844
Document: 0001628280-26-050844-index-headers.html0001628280-26-050844
Document: 0001628280-26-050844-index.html0001628280-26-050844
Document: 0001628280-26-050844.txt0001628280-26-050844
12 reports for ICLR
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+5▲ +3.92%Aug 6, 2026
Filters
Rows
Reports for ICLR — sortable, filterable
TypeNow
Aug 20, 2026
6w ago
6-K
NEUTRAL ★ 2/10
$174.27 $169.68▼ −2.63%▼ −2.63%$162.05 (−7.01%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$167.48 $169.31▲ +1.09%▲ +2.84%$162.05 (−3.24%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$167.48 $169.31▲ +1.09%▲ +2.84%$162.05 (−3.24%)
Aug 6, 2026
8w ago
6-K
BULLISH ★ 6/10
$161.17 $163.58▲ +1.50%▲ +0.90%$162.05 (+0.55%)
Jul 30, 2026
9w ago
6-K
BEARISH ★ 7/10
$165.53 $169.72▼ −2.53%▲ +1.43%$162.05 (+2.10%)
Jul 22, 2026
10w ago
6-K
NEUTRAL ★ 4/10
$167.28 $172.49▲ +3.11%▲ +0.22%$162.05 (−3.13%)
Jun 23, 2026
14w ago
6-K
BEARISH ★ 6/10
$158.17 $167.28▼ −5.76%▼ −3.83%$162.05 (−2.45%)
Jun 23, 2026
14w ago
6-K
NEUTRAL ★ 5/10
$158.17 $167.28▲ +5.76%▲ +3.83%$162.05 (+2.45%)
Jun 17, 2026
15w ago
6-K
NEUTRAL ★ 2/10
$146.00 $170.00▲ +16.44%▲ +15.91%$162.05 (+10.99%)
May 27, 2026
18w ago
6-K
BEARISH ★ 8/10
$136.80 $169.86▼ −24.17%▼ −27.31%$162.05 (−18.46%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (38h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access